Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

Advertisements

Nat. Rev. Urol. doi: /nrurol

An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Nat. Rev. Urol. doi: /nrurol

Figure 4 Types of urinary diversion

Figure 1 Male infertility and assisted reproduction globally

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Figure 1 Cellular processes involved in cancer development

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Urol. doi: /nrurol

Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2

Figure 2 Peptide vaccination using TAA-derived long peptides

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 Key elements of the proposed modified Delphi study

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Targets for monoclonal antibodies in B-cell lineages

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 CAR-T-cell design

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Prevention of antigen–antibody

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 The development process of the Asian

therapy and to block androgen action

Nat. Rev. Urol. doi: /nrurol

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Figure 5 Drugs that target WNT signalling

Figure 3 Algorithm for the determination of the clinical

Figure 3 Structure of different types of T-cell-engaging antibodies

Nat. Rev. Urol. doi: /nrurol

Platelet-derived growth factor receptors (PDGFRs) and ligand patterns.

Figure 6 Image sequence demonstrating coronal cuts on MRI

Figure 4 The molecular configuration of the CD20 molecule

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Template for standard pelvic lymphadenectomy

Figure 2 Site of action of checkpoint inhibitors and agonists being

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway

Nat. Rev. Urol. doi: /nrurol

Figure 1 CD36 structure and post-translational modifications

Nat. Rev. Cardiol. doi: /nrcardio

Volume 137, Issue 7, Pages (June 2009)

Nat. Rev. Urol. doi: /nrurol

Figure 4 The grey zone between active

An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:

Nat. Rev. Urol. doi: /nrurol

Figure 1 from D’Incalci et al.

Out, out darn toxin: the role of MDR in intestinal homeostasis

Schematic representation of the domain structures of insect enzymes involved in chitin metabolism. Schematic representation of the domain structures of.

Selectivity-determining regions

Structural organization of ALK and its fusion proteins.

Figure 1 Infection and resistance in urological practice

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2016.26 Figure 1 The structure of prostate-specific membrane antigen (PSMA), its binding sites for PSMA ligands and the most frequently used antibodies Figure 1 | The structure of prostate-specific membrane antigen (PSMA), its binding sites for PSMA ligands and the most frequently used antibodies. a | The short intracellular domain containing a binding site that can be targeted with 7E11 antibodies. b | The hydrophobic transmembrane region. The extracellular part of PSMA consists of section c | that contains two domains of unknown function and proline-rich and glycine-rich regions as linkers, d | that is the large catalytic domain, which contains a binding site for J591 antibodies as well as the active substrate recognition site that is being targeting by PSMA inhibitors and e | the final domain of unknown function to which a helical dimerization domain is localized. Maurer, T. et al. (2016) Current use of PSMA–PET in prostate cancer management Nat. Rev. Urol. doi:10.1038/nrurol.2016.26